Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

BACKGROUND: This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS). METHODS: Data from 350 adults with STS treated in five phase II trials with trabectedin were divided in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesne, A L, Judson, I, Maki, R, Grosso, F, Schuetze, S, Mehren, M V, Chawla, S P, Demetri, G D, Nieto, A, Tanovic, A, Blay, J-Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790176/
https://www.ncbi.nlm.nih.gov/pubmed/24022187
http://dx.doi.org/10.1038/bjc.2013.524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790176/
https://www.ncbi.nlm.nih.gov/pubmed/24022187
http://dx.doi.org/10.1038/bjc.2013.524

Ejemplares similares